The Ashwin is a monthly webzine for
ΑΩ Labs' customers -- Jan., 2002 Edition
Formatted to 600 pixel width for ease of reading and hardcopy reproduction
from the browser.
Related Links:
Ashwin Archives
Letters to the Editor - (Submissions)
|
Important Developments / Achievements at "ΑΩ" For 2001
|
"Save for the final moment
of your final hour,
a time known only to your Creator, there is, for every disease & every
affliction, a God-given botanical cure - if you only knew
where to find it - and would apply the faith and the
persistence to fully employ its original healing purpose..."
The Ashwin Letters:
Musings from the Divine Physicians
Cansema Revamped
& CanSupport Introduced
his year saw changes to the internal
Cansema formulas (which prior to 2001,
existed solely of the black
topical salve and two internal
variations - "capsules" and Tonic (I)).
Based on positive feedback from clinicians with
which ΑΩ Labs is associated, we
introduced Cansema Tonic III
in February -
a nutraceutical blend consisting
of extracts of graviola (annona muricata),
andrographis (peniculata), and chapparal
(larrea mexicata and tridentata),
all infused and stabilized in an aloe vera base for
maximum absorption.
The response
from the international community of alternative
health care practitioners has been quite positive.
One of the problems we had with many patients and
their clinicians with the first Cansema Tonic
was emetic responses tied to some of the herbal
alkaloids in the product. This, in turn, lead to
patient compliance issues. Despite clear instructions
that patients should only take the product
on a full stomach, a surprising number of users
would disregard or ignore these warnings altogether.
This coming
year (2002) we will be following
Tonic III with several new variations of
Cansema Tonic. Each formula will differ
in composition, ease of use, etc.
Internal Usage:
Salve vs. Tonic III
Cansema Black
Topical Salve is a well-known
escharotic salve. Patterned
after its predecessor, HerbVeil 8 (marketed under an
alliance with the now defunct Lenex Laboratories),
Cansema has been used by end users and doctors in countries
as far as
Ukraine, Japan, Australia, New Zealand, Equador, Colombia,
Trinidad, the U.S., Canada - to name a few.
♦ ΑΩ
The
CanSupport products, now
available in both aloe-infused, bioavailable liquid
form, as well as capsule
form, came out of a combination of our own
research with that of
Raintree Nutrition, which has focussed
extensively on the medicinal properties of
Amazonian herbs - primarily from Brazil.
(This work is not to be confused with our
own projects in Equador and Peru - which
have given rise to other herb-based products
we carry that come from the Western Amazon.)
Combining
these herbal compounds
with Tonic III
and HRx (see
article at right) produced ten distinct
nutraceutical "bundles."
Breaking
Into Bio-
Oxidative
Bio-oxidative
approaches (see sidebar on Otto Warburg at right)
involve uses of both ozone and
hydrogen peroxide.
In this area,
AO introduced Quikheal
Quick Healing Salves in May. The company has had
plans to inexpensively provide hydrogen
peroxide, but these plans have been detailed, due to
the complexity of setting up distribution for 35% H2O2
in various countries - made complicated by its
HazMat (Hazardous Material) rating.
But expect AO to
have its own product out in the first quarter.
|
Note to our Readers:
This is the fourth edition of the The Ashwin
(pronounced "Ah-sh' win"), covering January, 2002.
Previous editions are archived.
If you have questions,
email us.
|
n 2001 Alpha Omega Labs' approximately doubled its product
offerings, the result of intense research over the preceeding
two years.
Several groundbreaking
areas of note included the initial introduction and then
subsequent in-house manufacturing of what we termed
"pH Functional Concentrate Solutions." These included
H3O (the disinfecting, non-corrosive,
anticeptic "acid" version) and
and HRx (its "alkaline" version).
The ingredients and manner in which these products are made
were covered in the November Issue
of The Ashwin.
pH & anaerobiosis
A Nobel Prize Winner: Otto Warburg
Otto Heinrich
Warburg
(bio)
won the
Nobel Prize in Physiology or Medicine in 1931 for "his discovery
of the nature and mode of action of the respiratory enzyme."
He won a second Nobel Prize in 1944 for his discovery of
active groups of the hydrogen transferring enzymes.
But he also was a leading scientific authority of his time into
the cause and prevention of cancer. Years later, he would produce
paltry work, light in detail, outlining his thesis.
(See
The Prime Cause and Prevention of Cancer, a lecture he delivered
in June, 1966 - four years before his death at the age of 87).
But the world can only speculate what great work Warburg might
have produced had the establishment embraced his findings on
cancer with the vigor they did his revolutionary work on
enzymes.
". . . The medical world expects great things from your experiments
on cancer and other tumours, experiments which seem already
to be sufficiently far advanced to be able to furnish an
explanation for at least one cause of the destruction and
unlimited growth of these tumours . . . "
Professor E. Hammarsten
Presentation Speech
Nobel Price in Medicine, 1931
". . . there is no disease whose prime cause is better known,
so that today ignorance is no longer an excuse that one cannot
do more about prevention. That prevention of cancer will come there
is no doubt, for man wishes to survive. But how long prevention
will be avoided depends on how long the prophets of agnosticism
will succeed in inhibiting the application of scientific knowledge
in the cancer field. In the meantime, millions of men must die
of cancer unnecessarily."
Otto Warburg, 1966
(4 Years before his death at 87)
|
Medicinal Herbs
From Amazonia
The year 2001 saw the introduction of
traditional herbal remedies from Brazil,
Peru, and Equador.
Expect to an entire new line of products from Equador introduced by no later
than the second quarter.
Home Page
© 2001-2002 Alpha Omega Labs • Nassau, Bahamas • All
rights reserved. This page completed 01/05/2002.
|